Studies conducted on NL-001 shows that it is less susceptible to the manipulation that allows for abuse of opioids. It also complies with the FDA’s draft guidance, issued last week, which is intended to assist companies who wish to develop abuse deterrent opioid formulations.
NL-001 is expected to be launched in early 2015, according to the report.
More Articles on Pain Management:
Study: Minimally Invasive Lumbar Decompression Safe and Effective for Pain Relief
New York City to Restrict Painkiller Prescriptions in ER
Study: Researchers Learn About Possible Relief From Morphine Related Pain
